Bilia’s Annual General Meeting 2014 Gothenburg, Sweden,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bilia’s Annual General Meeting 2014

Gothenburg, Sweden, 2014-04-10 11:12 CEST (GLOBE NEWSWIRE) --

  • Dividend set at SEK 9 per share
  • Board, Chairman and public accounting firm re-elected
  • Guidelines for remuneration to Group Management adopted
  • New instruction for appointment of Nominating Committee adopted
  • Board given renewed mandate to resolve on buy-back/transfer of shares  

Today’s Annual General Meeting passed the following resolutions, which are in line with what was presented in the notice convening the AGM:

Accounts and dividend

After adopting the Income Statement and Balance Sheet and the Consolidated Income Statement and Consolidated Balance Sheet, the AGM adopted the proposed cash dividend of SEK 9.00 per share (6.00). The record date was set at 15 April and the dividend is expected to be distributed through Euroclear on 22 April 2014. The remaining earnings were carried forward to a new account.

Discharge from liability and election of Board of Directors and public accounting firm

The AGM discharged the members of the Board and the Managing Director from liability for the financial year. The AGM resolved to re-elect the entire Board of Directors, consisting of: Per Avander, Ingrid Jonasson Blank, Anna Engebretsen, Jack Forsgren, Fredrik Grevelius, Mats Holgerson, Svante Paulsson, Jan Pettersson, Mats Qviberg and Jon Risfelt. The AGM also re-elected Mats Qviberg as Chairman. After the meeting, the Board appointed Jan Pettersson as Deputy Chairman.

The AGM resolved that the directors’ fees should be as follows: the Chairman of the Board receives SEK 300,000, the Deputy Chairman SEK 300,000, other Board members who do not receive a salary from the company receive SEK 180,000 each, the chairman of the Audit Committee receives SEK 50,000, the members of the Audit Committee receive SEK 25,000 each, and the chairman of the Compensation Committee receives SEK 25,000. Fees to chairmen and committees are thus unchanged. Remuneration to the Deputy Chairman of the Board was raised by SEK 25,000, while remuneration to other Board members was raised by SEK 5,000 compared with last year.

KPMG AB was re-elected as the public accounting firm for the period up until the next AGM in 2015.

Guidelines for remuneration to Group Management

Proposed guidelines for remuneration to the Group Management were adopted by the AGM. The guidelines are unchanged from last year.

Nominating Committee instruction

The proposed instruction for appointment of the Nominating Committee was adopted. The number of members can vary between 4 and 5 and they shall consist of major shareholders along with the Chairman of the Board. The instruction shall apply until further notice.  

Acquisition or transfer of own shares

The AGM authorised the Board of Directors to a) resolve to buy back the company’s own shares, whereby Bilia’s holding may never exceed 10 per cent of the total number of shares, and b) resolve to transfer acquired shares, either as a means of payment in conjunction with an acquisition or by direct sale on the stock exchange.

Gothenburg, 10 April 2014

Bilia AB (publ)

         For further information, please contact Per Avander, Managing Director and CEO, or          Gunnar Blomkvist, CFO, Bilia AB, tel. +46 31 709 55 00.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 938

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 240

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 188

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 462

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 289

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 309

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 261

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Sonic Partners with Obsessed Garage for Home Garage Solutions

Updated Category News Views 147

Sonic Teams Up with Obsessed Garage to Transform Home Garages Sonic, a front-runner in delivering high-quality tool solutions and equipment, has recently announced an exciting partnership with Obsessed Garage. This collaboration aims to cater to home garage enthusiasts who demand tools and storage solutions that match the quality standards utilized by professionals in the...

Continue Reading
Investors of Sun Communities, Inc. Urged to Act Before Deadline

Updated Category News Views 167

Important Update for Sun Communities, Inc. Investors There is a significant call to action for investors of Sun Communities, Inc. as a class action lawsuit has been filed against the company, urging those affected to act promptly. This is a crucial moment for investors who purchased securities from the company during a specific period. Legal representation is being...

Continue Reading
XOMA Stock Reaches New Heights: Key Developments and Insights

Updated Category News Views 67

XOMA Stock Performance Overview XOMA Ltd's stock has recently made headlines by reaching a remarkable 52-week high, with shares trading at an impressive $30.49. This achievement not only signifies a significant milestone for the company but also highlights a robust year-over-year growth that can't be overlooked. Investors have observed a substantial increase of 73.82% in...

Continue Reading
Evolv Technologies Faces Turmoil with Executive Departures

Updated Category News Views 230

Evolv Technologies Faces Turmoil with Executive Departures Evolv Technologies Holdings (NASDAQ: EVLV) is navigating turbulent times following the resignation of its Chief Financial Officer, Mark Donohue. His departure comes amid serious allegations of improper revenue recognition practices that have raised questions about the company's integrity and financial health....

Continue Reading
Editas Medicine: Financial Insights and Market Strategies Revealed

Updated Category News Views 56

Editas Medicine Maintains Price Target Amidst Financial Developments Recently, Leerink Partners reaffirmed a Market Perform rating for Editas Medicine (NASDAQ: EDIT), keeping a price target steady at $8.00. This decision comes closely after the company announced a substantial financing agreement with DRI Healthcare Trust. Under this agreement, Editas is set to receive an...

Continue Reading